calcimedica inc glp-1 receptor agonist weight management diabetes treatments 🔴GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity⤵️ #2024Review #openaccess 🔹https://academic.oup.com/ckj/article/17 GLP-1 Receptor Agonists as Treatments

This finding suggests that DPP4 inhibitors, owing to their GLP-1-enhancing actions, may have a direct beneficial effect on cardiomyocyte function

Weight loss was consistent and progressive, starting at 3.93% at three months and reaching 7.87% at twelve months. In addition, several case series studies have demonstrated benefits of GLP-1s in kidney and pancreas transplant recipients, including lowering blood glucose levels and providing renal protective effects. GLP-1 RAs would be advantageous in liver transplant recipients due to their renal clearance, avoiding interference with immunosuppressant drug metabolism

Runge, S

41 Dapagliflozin FDA product information (2023)

Our coverage of tirzepatide appetite suppression timelines addresses many of the same gastrointestinal management strategies applicable to retatrutide protocols

Table 1 Summary of studies reporting efficacy and safety of GLP-1 RAs therapy in SIH and SID